Literature DB >> 26464703

Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis.

Gui Cheng1, Min Li1, Jun Wu1, Mei Ji1, Cheng Fang1, Hongbing Shi1, Danxia Zhu1, Lujun Chen1, Jiemin Zhao1, Liangrong Shi1, Bin Xu1, Xiao Zheng1, Changping Wu1, Jingting Jiang1.   

Abstract

As a negative regulatory molecule, T-cell immunoglobulin-and mucin domain-3 (Tim-3) plays a crucial role in the tumor immunological tolerance. In the present study, we aimed to determine the Tim-3 expression in gastric cancer tissue and its relationship with clinicopathological parameters and prognosis. The Tim-3 expression was assessed in 52 gastric cancer specimens and 15 gastritis tissues by flow cytometry, and gastritis tissues served as the control. As a result, we found that the Tim-3 expressions on CD4(+)T cells and CD8(+)T cells in gastric cancer tissue was significantly higher than those in gastritis tissue (P=0.022, P=0.047, respectively). The median expression level of Tim-3 on CD4(+)T cells were significantly correlated with clinicopathological parameters, such as tumor size, lymph node metastasis, the depth of tumor invasion and TNM staging (P=0.042, P=0.026, P=0.001, P=0.003, respectively), while it was not correlated with sex, age and histological subtype (all P>0.05). In CD8(+)T cells, the Tim-3 expression was relevant to tumor invasion and TNM staging (P=0.035, P=0.017, respectively), while it was irrelevant to other clinicopathological parameters (all P>0.05). Additionally, Kaplan-Meier survival curves showed that the median overall survival time of patients with lower Tim-3 expression was greater than that of patients with higher Tim-3 expression in CD4(+)T cells and CD8(+)T cells (χ(2)=18.036, P<0.001 and χ(2)=18.036, P<0.001, respectively). Moreover, the multivariate analysis revealed that the Tim-3 expression and TNM stage were independent prognostic factors for gastric cancer patients (P=0.029, P=0.043 and P=0.003, respectively). These results suggest that Tim-3 played an important role in the development and progression of gastric cancer, and it could be used as an independent prognostic factor for gastric cancer patients.

Entities:  

Keywords:  T-cell immunoglobulin-and mucin domain-3 (Tim-3); flow cytometry; gastric cancer; prognosis

Mesh:

Substances:

Year:  2015        PMID: 26464703      PMCID: PMC4583935     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.

Authors:  Ana C Anderson; David E Anderson; Lisa Bregoli; William D Hastings; Nasim Kassam; Charles Lei; Rucha Chandwaskar; Jozsef Karman; Ee W Su; Mitsuomi Hirashima; Jeffrey N Bruce; Lawrence P Kane; Vijay K Kuchroo; David A Hafler
Journal:  Science       Date:  2007-11-16       Impact factor: 47.728

2.  Family-based association study of Tim-1 and Tim-3 gene polymorphisms with childhood asthma in Chinese trios.

Authors:  Qi-Wen Wu; Peng-Cheng Cai; Ling Wang; Yi-Rong Li; Ling-Ling Kong; Li-Hua Hu
Journal:  Int Arch Allergy Immunol       Date:  2009-06-04       Impact factor: 2.749

3.  Expression of the Th1-specific cell-surface protein Tim-3 increases in a murine model of atopic asthma.

Authors:  Wei-Kun Hu; Xiao-Xia Lu; Shuo Yang; Guo-Peng Xu; Fen Lan; Shi-Xin Chen; Wang Ni; Wei-Ning Xiong; Sheng-Dao Xiong
Journal:  J Asthma       Date:  2009-11       Impact factor: 2.515

4.  Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion.

Authors:  Xiaoyuan Huang; Xiangyang Bai; Yang Cao; Jingyi Wu; Mei Huang; Duozhuang Tang; Si Tao; Tao Zhu; Yanling Liu; Yang Yang; Xiaoxi Zhou; Yanxia Zhao; Mingfu Wu; Juncheng Wei; Daowen Wang; Gang Xu; Shixuan Wang; Ding Ma; Jianfeng Zhou
Journal:  J Exp Med       Date:  2010-02-22       Impact factor: 14.307

5.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

6.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

7.  Gastric cancer.

Authors:  Henk H Hartgrink; Edwin P M Jansen; Nicole C T van Grieken; Cornelis J H van de Velde
Journal:  Lancet       Date:  2009-07-20       Impact factor: 79.321

8.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

9.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

10.  Analysis of Tim-3 as a therapeutic target in prostate cancer.

Authors:  Yong-Rui Piao; Zhe-Hu Jin; Kui-Chang Yuan; Xuan-Shun Jin
Journal:  Tumour Biol       Date:  2014-08-15
View more
  15 in total

1.  Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.

Authors:  Paweł Łaniewski; Haiyan Cui; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  NPJ Precis Oncol       Date:  2020-08-03

2.  An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.

Authors:  Xiaowen Zhao; Pingfan Wu; Dongling Liu; Changtian Li; Ling Xue; Zhe Liu; Meng Zhu; Jie Yang; Ziyi Chen; Yaling Li; Yali She
Journal:  J Healthc Eng       Date:  2022-04-25       Impact factor: 3.822

3.  Tumor apelin, not serum apelin, is associated with the clinical features and prognosis of gastric cancer.

Authors:  Meiyan Feng; Guodong Yao; Hongwei Yu; Yu Qing; Kuan Wang
Journal:  BMC Cancer       Date:  2016-10-12       Impact factor: 4.430

Review 4.  The Progress of T Cell Immunity Related to Prognosis in Gastric Cancer.

Authors:  Ming Wei; Duo Shen; Sachin Mulmi Shrestha; Juan Liu; Junyi Zhang; Ying Yin
Journal:  Biomed Res Int       Date:  2018-02-27       Impact factor: 3.411

5.  Tim-3 Up-regulation in Patients with Gastric Cancer and Peptic Ulcer Disease

Authors:  Mahdieh Naghavi-Alhosseini; Mohsen Tehrani; Abolghasem Ajami; Alireza Rafiei; Tarang Taghvaei; Laleh Vahedi-Larijani; Hadi Hossein-Nataj; Hossein Asgarian-Omran
Journal:  Asian Pac J Cancer Prev       Date:  2017-03-01

Review 6.  TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.

Authors:  Wenwen Du; Min Yang; Abbey Turner; Chunling Xu; Robert L Ferris; Jianan Huang; Lawrence P Kane; Binfeng Lu
Journal:  Int J Mol Sci       Date:  2017-03-16       Impact factor: 5.923

7.  Functional variants of TIM-3/HAVCR2 3'UTR in lymphoblastoid cell lines.

Authors:  Feifei Pu; Fengxia Chen; Zhicai Zhang; Jing Feng; Ping Xia
Journal:  Future Sci OA       Date:  2018-03-15

8.  Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.

Authors:  Ritu Shrestha; Prashanth Prithviraj; Matthew Anaka; Kim R Bridle; Darrell H G Crawford; Bijay Dhungel; Jason C Steel; Aparna Jayachandran
Journal:  Front Oncol       Date:  2018-07-13       Impact factor: 6.244

Review 9.  TIM-3, a promising target for cancer immunotherapy.

Authors:  Yayi He; Jie Cao; Chao Zhao; Xuefei Li; Caicun Zhou; Fred R Hirsch
Journal:  Onco Targets Ther       Date:  2018-10-16       Impact factor: 4.147

10.  Vaginal microbiota, genital inflammation, and neoplasia impact immune checkpoint protein profiles in the cervicovaginal microenvironment.

Authors:  Paweł Łaniewski; Haiyan Cui; Denise J Roe; Dana M Chase; Melissa M Herbst-Kralovetz
Journal:  NPJ Precis Oncol       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.